N
Nexalin Technology Inc.
Biotechnology: Electromedical & Electrotherapeutic Apparatus company
Key Metrics of Nexalin Technology Inc.
Revenue$111K▼ 91.6% YoYFY 2023
Operating income−$5.7M▼ 210.8% YoY
Net profit−$4.6M▼ 173.8% YoY
Shareholders' equity$3.2M
Market cap$1.7MNXL · $1.64
Competitors10identified
About Nexalin Technology Inc.
Sectors
Company details
- Founded
- 2022
- Listed
- Nasdaq: NXL (since 2022)
Operational Areas of Nexalin Technology Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameNexalin Technology Inc.
TickerNXL
ExchangeNasdaq
CountryUnited States
SEC CIK0001527352
Listed since2022
IndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
NXL · Nasdaq · SEC CIK 0001527352
Last price · 29 Oct 2026
$1.64
−4.09%
Market cap$1.7M
P/E—On FY 2023 diluted EPS
Volume71,433
SectorHealth CareBiotechnology: Electromedical & Electrotherapeutic Apparatus
Country · IPOUnited StatesListed 2022
NXL share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Nexalin Technology Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States |
Similar companies
A
Anthem Biosciences (India)Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
P
Premium Serums & Vaccines Pvt. Ltd. (India)Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
B
Bharat Serums And Vaccines LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
I
International Biotech Park LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
B
Bharat Immunologicals And Biologicals Corporation LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
H
Hester Biosciences LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
M
Medicamen Biotech LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
B
Biological E. LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.